Last weeks round-up; 2 – 6 December 2019

EMA GUIDANCE ON NITROSAMINE ASSESSMENTS

CMDh has issued an update to the practical guidance on Nitrosamine assessments. It is confirmed that MAHs can combine several MAs in one template of the risk assessment step 1 outcome, where the outcome is the same. However, national requirements too as mentioned later in the guidance needs to be considered. The national requirements may not necessarily be overruled by the general possibility given by CMDh. The full guidance document can be found under this link https://lnkd.in/dBHf63p EMA

HMA/EMA BIG DATA TASK FORCE REPORTS

Massive amounts of data are generated on a daily basis that could potentially be harnessed to support medicines regulation. The EMA and HMA have established a joint task force to investigate the potential role of ‘big data’ in the context of medicines development and regulation in the EU. A series of Subgroup reports were issued on 27th Nov 2019, links to the different subgroup reports can be found here https://lnkd.in/dU6Kwu2. Topics include, Clinical Trial and Imaging, Genomics, Genetics Transcriptomics and Epigenetics, Observational Data and Bioanalytical Omics.

NEW CMDH BEST PRACTICE GUIDE ON MULTILINGUAL PACKAGING

A new CMDh Best Practice Guide on Multilingual Packaging was published this month, November 2019.  Multilingual packaging relates to the use of two or more languages on the immediate and /or outer packaging and/or package leaflet of a medicinal product. The published guidance is aimed to assist applicants in creating multilingual packages which are recognised for their importance in maintaining products in EU markets. To view the guidance in full, please see: http://bit.ly/37QiHOI

SECOND CORRIGENDUM OF MDR (EU) 2017/745 CONCERNING CLASS I MEDICAL DEVICES

The council of the European Union published the second corrigendum to the EU Medical Devices Regulation (MDR) on the 25th November. The most significant changes relate to Class I medical devices which are sterile, include a measuring function, or are reusable surgical instruments. The corrigendum will mean that manufacturers would have an additional 4 years up to 26th May 2024 to comply with the new regulations in full. The changes proposed in the second corrigendum must be formally adopted by the European Parliament to take effect. MDR Corrigendum 13081/19 is linked here https://bit.ly/381YEgB with the English version starting on page 43 of the document.

BREXIT MEDICINES SHORTAGES

EMA has just updated its Q&A document (Link – https://lnkd.in/dg7PUay ) on the work being done to avoid medicines shortages following the UKs exit from EU. Medicines agencies will make information on Medicines procedures available via usual means, therefore, there is also a link therein to where details of medicines subject to ongoing shortages in EU countries can be found.

Last weeks round-up; 14 – 18 October 2019

EVALUATION OF THE EU BLOOD, TISSUE AND CELLS LEGISLATION

On 11 October 2019, the European Commission published its evaluation of the EU blood, tissues and cells legislation. An executive summary is also available. This was the first evaluation of the legislation since the adoption of the basic Acts in 2002 (blood) and 2004 (tissues and cells). Further information and a link to the evaluation can be found under this link https://lnkd.in/ds48XHY. The results of the evaluation will be disseminated at a Conference in Brussels on 28 October 2019.

EMA: UPDATED VERSIONS OF eAFs NOW AVAILABLE

EMA has just issued version 1.23.1.3 of the 4 electronic Application Forms (eAF), which are now available on the eAF website, along with new release notes and a release milestone plan. This release is a bug fix release to correct a number of issues which affect the forms. The bug fix release does not affect the Data Exchange Standard (DES). Applicants are reminded that the version of the form should not be changed during an ongoing procedure. https://lnkd.in/de7AFKu

PAEDIATRIC COMMITTEE (PDCO) MEETING MINUTES

An overview of Pedmed-NL (the former Dutch Medicines for Children Research Network) was presented. The network has been involved in the development of the Dutch Paediatric Formulary (kinderformularium), the establishment of European Paediatric Translational Research Infrastructure (EPTRI) and Paediatric Clinical Research Infrastructure (PEDCRIN) as well as in the planning of clinical trials, mainly via Connect4Children (C4C). The network was relaunched in 2018 as PedmedNL with main goal to facilitate and support the conduct of C4C proof of viability studies (by 2023). The main goal beyond 2023 is to create a sustainable network for research in children. The minutes can be found under; https://lnkd.in/dpNCPqQ

UK WITHDRAWAL FROM EU: EMA RELOCATION TO AMSTERDAM

EMA has recently reported a further 6% reduction in workforce as a result of relocating to Amsterdam. As a result EMA is reviewing its organisational structure and looking to set up task forces that will focus on key priorities for the European medicines regulatory network further details can be found here: https://lnkd.in/dx49VpY

EMA ADVISES COMPANIES ON STEPS TO TAKE TO AVOID NITROSAMINES IN HUMAN MEDICINES *UPDATE*

As previously advised, EMA has requested all EU marketing authorisation holders of medicinal products containing chemically synthesised APIs to review their medicines within the next 6 months for the presence of nitrosamines. Real Regulatory has both the expertise and resource to support this review process. For more information on the EMA recommendation, including a Q&A quide: https://lnkd.in/erne7TZ

EMA PRIME ELIGIBILITY REQUESTS

EMA has just published its deadlines and timetable for PRIME Eligibility request assessments for 2020. Further details can be found here; https://lnkd.in/d7Z8x6J